In the swiftly evolving field of oncology investigation, exact and economical mutation screening is very important for developing specific therapies. The KRAS solutions Platform plays a pivotal position Within this landscape by providing detailed alternatives for KRAS mutation profiling and Investigation. KRAS mutations, present in about 95% of RAS